Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Trial Type:  Treatment
Keywords/Phrases:  "histone deacetylase"
Results 1-25 of 99 for your search:
Start Over
Vorinostat and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CTRC 08-52, NCI-2012-01694, HSC20080462H, NCT01023737
Radiation Therapy and Romidepsin with or without Poly ICLC in Treating Patients with Previously Treated Stage IIA-IVA Mycosis Fungoides
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: S13-00686, NCI-2014-00279, i13-00686, NYU S13-00686, NCT02061449
Efficacy, Safety and Tolerability Study of SHAPE in IA, IB or IIA Cutaneous T-cell Lymphoma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: SHP-141-003, NCI-2014-02164, NCT02213861
Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 0103-014, NCI-2013-02087, NCT02018926
Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 0103-018, NCI-2014-02470, NCT02236195
Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: AMC-078, NCI-2011-02511, CDR0000689900, NCT01249443
Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple Myeloma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: ACE-MM-104, NCI-2014-01879, NCT02189343
Ruxolitinib Phosphate and Pracinostat in Treating Patients with Myelofibrosis
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2014-0445, NCI-2015-00002, NCT02267278
Vorinostat in Treating Patients with Metastatic Melanoma of the Eye
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: AAAO5917, NCI-2012-00860, CUMC-IRBAAAO5917, MSKCC-12-027, 9111, 12-027, NCT01587352
Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple Myeloma
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: ACE-MM-101, NCI-2012-01280, NCT01583283
Vorinostat, Gemcitabine Hydrochloride, and Docetaxel in Treating Patients With Soft Tissue Sarcoma That is Metastatic or Cannot Be Removed By Surgery
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-104, NCI-2013-01735, UPCI 12-104, NCT01879085
Mocetinostat in Treating Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma or Follicular Lymphoma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 14-106, NCI-2014-02289, NCT02282358
Vorinostat and Hydroxychloroquine or Regorafenib in Treating Patients with Refractory Metastatic Colorectal Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CTMS 14-2015, NCI-2015-00203, 14-2015, 2015, HSC20150178H, NCI-2015-00175, NCT02316340
Panobinostat and Carfilzomib in Treating Patients with Relapsed or Refractory Multiple Myeloma
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: WCI2011-11MMRC036, NCI-2012-00161, 49368, IRB00049368, MMRC: 036, NCT01549431
Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 12-0288-04, NCI-2012-01131, NCT01686165
Lenalidomide and Romidepsin with or without Dexamethasone in Treating Patients with Recurrent or Refractory Hodgkin Lymphoma, Mature T-cell Lymphoma, or Multiple Myeloma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 80
Trial IDs: 1112009392, NCI-2015-00921, RM-PTCL-PI-0021, NCT01742793
Romidepsin and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients with Stage IB-IVB Relapsed or Refractory T-cell Lymphomas
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 112516, NCI-2014-01722, CC#112516, RM-CTCL-PI-0012, UCSF CC# 112516, UCSF Protocol Number 112516, NCT01902225
Azacitidine and Entinostat Followed by Nivolumab or Nivolumab Alone in Treating Patients with Recurrent Metastatic Non-small Cell Lung Cancer
Phase: Phase II
Type: Treatment
Age: Over 18
Trial IDs: J1353, NCI-2013-02334, J1353/ NA_00084192, NA_00084192, NA_00084192/CIR00003289, NCT01928576
Panobinostat, Lenalidomide, Bortezomib, and Dexamethasone in Treating Patients with Relapsed or Refractory Multiple Myeloma
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 13-262, NCI-2013-02008, CLBH589BUS82T, NCT01965353
Ixazomib, Panobinostat, and Dexamethasone in Treating Patients with Relapsed or Refractory Multiple Myeloma
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CASE 4A13, NCI-2014-00228, CLBH589DUS92T, NCI-2014-00267, US92T, NCT02057640
HDAC6 Inhibitor ACY-1215 in Treating Patients with Relapsed or Refractory Non-Hodgkin Lymphoma or Hodgkin Lymphoma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: AAAM4054, NCI-2014-01521, IRB-AAAM4054, NCT02091063
Exemestane with or without Entinostat in Treating Postmenopausal Patients with Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: E2112, NCI-2014-00746, ECOG-E2112, NCT02115282
Gemcitabine Hydrochloride, Nab-Paclitaxel, Radiation Therapy, Sorafenib Tosylate, and Vorinostat in Treating Patients with Previously Untreated Pancreatic Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MCC-12-07328, NCI-2015-00017, NCT02349867
Vorinostat and Combination Chemotherapy with Rituximab in Treating Patients with HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: AMC-075, NCI-2011-02508, AMC #75, CDR0000683379, NCT01193842
A Study Of Panobinostat In Children With Refractory Hematologic Malignancies
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 8 to 21
Trial IDs: T2009-012, NCI-2012-00054, NCT01321346
Start Over